A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-center, Single-dose, Dose-escalating Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of CDP6038 in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2014
At a glance
- Drugs Olokizumab (Primary) ; Olokizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors UCB
- 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
- 21 Jan 2011 New trial record